Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026)
Molecular Partners Ag's (MOLN) quarterly Asset Utilization Ratio came in at 0.05 in Q2 2026, up 13.63% year-over-year from 0.05 in Q2 2025, and up 13.63% quarter-over-quarter from 0.05 in Q2 2025.
Analysis
Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Asset Utilization Ratio for 6 consecutive years, with 0.05 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio rose 13.63% year-over-year to 0.05 in Q2 2026; TTM through Jun 2026 was 0.05, a 13.63% increase from a year earlier, with the FY2024 full-year figure at 0.03, down 10.34% from the prior year.
- Asset Utilization Ratio was 0.05 for Q2 2026 at Molecular Partners Ag, up from 0.05 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.78 in Q3 2023 and troughed at 0.04 in Q4 2023.
- A 5-year average of 0.26 and a median of 0.06 in 2022 frame the typical range for Asset Utilization Ratio.
- The widest YoY moves for Asset Utilization Ratio: up 1209.21% in 2023, down 95.19% in 2023.
- Over 5 years, Asset Utilization Ratio stood at 0.74 in 2022, then slumped by 95.19% to 0.04 in 2023, then grew by 15.88% to 0.04 in 2024, then gained by 16.87% to 0.05 in 2025, then grew by 13.63% to 0.05 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.05 (Q2 2026), 0.05 (Q2 2025), and 0.04 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | 0.01 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.05 |
| Jun 30, 2025 | 0.05 |
| Dec 31, 2024 | 0.04 |
| Sep 30, 2024 | 0.05 |
| Jun 30, 2024 | 0.05 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.04 |
| Sep 30, 2023 | 0.78 |
| Jun 30, 2023 | 0.76 |
| Mar 31, 2023 | 0.78 |
| Dec 31, 2022 | 0.74 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | 0.07 |
| Mar 31, 2022 | 0.06 |
| Dec 31, 2021 | 0.08 |